Targeting the neurotoxic species in Alzheimer's disease: Inhibitors of Aβ oligomerization

FASEB Journal

Volumn 18, Issue 12, 2004, Pages 1366-1372

  De Felice, Fernanda G ^a   Vieira, Marcelo N N ^a   Saraiva, Leonardo M ^a   Figueroa Villar, J Daniel ^b   Garcia Abreu, José ^a   Liu, Roy ^c   Chang, Lei ^c   Klein, Willian L ^c   Ferreira, Sérgio T ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b MILITARY INSTITUTE OF ENGINEERING   (Brazil)

^c Dept of Neurobiology and Physiology   (United States)

Author keywords

Amyloid; Neuroprotection; Oligomers; Small molecule inhibitors

Indexed keywords

2 AMINO 4 CHLOROPHENOL; 2 HYDROXY 3 ETHOXYBENZALDEHYDE; 4 AMINOPHENOL; AMYLOID; AMYLOID BETA PROTEIN; AROMATIC COMPOUND; NEUROPROTECTIVE AGENT; NEUROTOXIN; OLIGOMER; PARA ANISIDINE; PROTOCATECHUIC ACID; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DEMENTIA; ELECTRON MICROSCOPY; EMBRYO; HIPPOCAMPUS; HYDROPHOBICITY; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; HIPPOCAMPUS; INHIBITORY CONCENTRATION 50; NEURONS; NEUROPROTECTIVE AGENTS; PROTEIN STRUCTURE, QUATERNARY; RATS; SENILE PLAQUES; SOLUBILITY; THIAZOLES;

ANIMALIA;

EID: 4344688011     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.04-1764com     Document Type: Article

References (44)

1. Haass, C., and De Strooper, B. (1999) The presenilins in Alzheimer's disease - proteolysis holds the key. Science 286, 916-919
2. Selkoe, D. J. (2002) Alzheimer's disease is a synaptic failure. Science 298, 789-791
3. Yankner, B. A. (2000) Apoptosis in the nervous system. Nature (London) 407, 802-809
4. Caughey, B., and Lansbury, P. T. (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298
5. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1993) Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13, 1676-1687
6. Lorenzo, A., and Yankner, B. A. (1994) Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247
7. Grace, E. A., Rabiner, C. A., and Busciglio, J. (2002) Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 114, 265-273
8. Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 95, 6448-6453
9. Wang, H. W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., et al. (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res. 924, 133-140
10. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Rowan, M. J., and Selkoe, D. J. (2002) Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem. Soc. Trans. 30, 552-557
11. Kim, H. J., Chae, S. C., Lee, D. K., Chromy, B., Lee, S. C., Park, Y. C., Klein, W. L., Krafft, G. A., and Hong, S. T. (2003) Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J. 17, 118-120
12. Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., and Glabe, C. G. (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489
13. De Felice, F. G., and Ferreira, S. T. (2002) Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell. Mol. Neurobiol. 22, 545-563
14. Lashuel, H. A., Hartley, D. M., Balakhaneh, D., Aggarwal, A., Teichberg, S., and Callaway, D. J. (2002) New class of inhibitors of amyloid-beta fibril formation. Implications for the mechanism of pathogenesis in Alzheimer's disease. J. Biol. Chem. 277, 42881-42890
15. Li, J., Zhu, M., Manning-Bog, A. B., Di Monte, D. A., and Fink, A. L. (2004) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J. 18, 962-964
16. Lin, S. J., Shiao, Y. J., Chi, C. W., and Yang, L. M. (2004) Abeta aggregation inhibitors. Synthesis and biological activity of phenylazo benzenesulfonamides. Bioorg. Med. Chem. Lett. 14, 1173-1176
17. Ono, K., Hasegawa, K., Naiki, H., and Yamada, M. (2004) Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 75, 742-750
18. Klein, W. L., Krafft, G. A., and Finch, C. E. (2001) Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224
19. Cohen, F. E., and Kelly, J. W. (2003) Therapeutic approaches to protein-misfolding diseases. Nature (London) 426, 905-909
20. Chang, L., Bakhos, L., Wang, Z., Venton, D. L., and Klein, W. L. (2003) Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20, 305-313
21. Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., and Klein, W. L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595-605
22. De Felice, F. G., Houzel, J. C., Garcia-Abreu, J., Louzada, P. R., Jr., Afonso, R. C., Meirelles, M. N., Lent, R., Neto, V. M., and Ferreira, S. T. (2001) Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. FASEB J. 15, 1297-1299
23. Gazit, E. (2002) A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J. 16, 77-83
24. Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X. D., McKay, D. M., Tintner, R., and Frangione, B. (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258, 126-129
25. Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., and Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580
26. Dickson, D. W., Crystal, H. A., Bevona, C., Honer, W., Vincent, I., and Davies, P. (1995) Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285-298
27. Lue, L. F., Kuo, Y. M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., and Rogers, J. (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862
28. McLean, C. A., Cherny, R. A., Fraser, F. W., Fuller, S. J., Smith, M. J., Beyreuther, K., Bush, A. I., and Masters, C. L. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860-866
29. Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., and Klein, W. L. (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 100, 10417-10422
30. Xia, W., Zhang, J., Kholodenko, D., Citron, M., Podlisny, M. B., Teplow, D. B., Haass, C., Seubert, P., Koo, E. H., and Selkoe, D. J. (1997) Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 7977-7982
31. Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., and Selkoe, D. J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (London) 416, 535-539
32. Koistinaho, M., Ort, M., Cimadevilla, J. M., Vondrous, R., Cordell, B., Koistinaho, J., Bures, J., and Higgins, L. S. (2001) Specific spatial learning deficits become severe with age in beta-amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl. Acad. Sci. USA 98, 14675-14680
33. Westerman, M. A., Cooper-Blacketer, D., Mariash, A., Kotilinek, L., Kawarabayashi, T., Younkin, L. H., Carlson, G. A., Younkin, S. G., and Ashe, K. H. (2002) The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22, 1858-1867
34. Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (London) 400, 173-177
35. Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., Mount, H. T., Nixon, R. A., Mercken, M., Bergeron, C., Fraser, P. E., St. George-Hyslop, P., and Westaway, D. (2000) Abeta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (London) 408, 979-982
36. Morgan, D., Diamond, D. M., Gottschall, P. E., Ugen, K. E., Dickey, C., Hardy, J., Duff, K., Jantzen, P., DiCarlo, G., Wilcock, D., Connor, K., Hatcher, J., Hope, C., Gordon, M., and Arendash, G. W. (2000) A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (London) 408, 982-985
37. Kotilinek, L. A., Bacskai, B., Westerman, M., Kawarabayashi, T., Younkin, L., Hyman, B. T., Younkin, S., and Ashe, K. H. (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331-6335
38. Dodart, J. C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5, 452-457
39. Birmingham, K., and Frantz, S. (2002) Set back to Alzheimer vaccine studies. Nat. Med. 8, 199-200
40. Lambert, M. P., Viola, K. L., Chromy, B. A., Chang, L., Morgan, T. E., Yu, J., Venton, D. L., Krafft, G. A., Finch, C. E., and Klein, W. L. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J. Neurochem. 79, 595-605
41. Raghu, P., Reddy, G. B., and Sivakumar, B. (2002) Inhibition of transthyretin amyloid fibril formation by 2,4-dinitrophenol through tetramer stabilization. Arch. Biochem. Biophys. 400, 43-47
42. Cardoso, I., Merlini, G., and Saraiva, M. J. (2003) 4′-Iodo- 4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 17, 803-809
43. Chromy, B.A., Nowak, R.J., Lambert, M. P., Viola, K. L., Chang, L., Velasco, P. T., Jones, B. W., Fernandez, S. J., Lacor, P. N., Horowitz, P., Finch, C. E., Krafft, G. A., and Klein, W. L. (2003) Self-assembly of Abeta (1-42) into globular neurotoxins. Biochemistry 42, 12749-12760
44. Chang, L., Bakhos, L., Wang, Z., Venton, D. L., and Klein, W. L. (2003) Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci. 20, 305-314